Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

Food and Drug Administration Approves Once-a-Day Pill for HIV

August 28, 2012

Gilead Science's once-a-day HIV treatment that combines four HIV drugs into one tablet has been approved by the Food and Drug Administration. Gilead says Stribild, previously known as Quad, will cost about $28,500 a year.

Stribild is the third once-a-day HIV treatment Gilead has brought to market, after Atripla in 2006 and Complera in 2011. Stribild does not represent a significant leap medically compared to the others. In clinical trials that led to its approval, Stribild was shown to be roughly equivalent to Atripla and to another combination, though without some of Atripla's psychiatric side effects. Approximately 88 percent-90 percent of patients who took Stribild had undetectable HIV in their blood after 48 weeks, compared to 84 percent taking Atripla and 87 percent taking a combination of Gilead's Truvada, Bristol-Myers Squibb (BMS)'s Reyataz, and Abbott's Norvir.

Stribild is composed of emtricitabine and tenofovir, which are also found in Atripla and Complera, as well as elvitegravir and cobicistat -- neither of which has been approved for use independently. What could differentiate Stribild commercially is that Gilead owns all the ingredients, whereas Atripla includes a BMS drug and Complera contains a drug from Johnson & Johnson -- meaning Gilead must split profits from those drugs.

Michael Weinstein, president of the AIDS Healthcare Foundation, which treats more than 100,000 HIV/AIDS patients worldwide, called Gilead's pricing of Stribild "shockingly irresponsible." "It's just unsustainable at these levels," he said.

Gilead spokesperson Erin Rau said price "reflects a reasonable return on our product development investment." The company plans to provide discounts to state AIDS Drug Assistance Programs, and offer programs to help privately insured patients with Stribild's cost, she said. Further, Gilead has granted certain Indian generic drug manufacturers rights to produce Stribild for distribution in poor countries.

Back to other news for August 2012

Adapted from:
New York Times
08.28.2012; Andrew Pollack


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More News on Stribild (Elvitegravir/Cobicistat/FTC/Tenofovir)

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement